thromboxane a2 receptor

Terbogrel is an oral thromboxane A2 receptor antagonist (IC50 is about 10 nM) and thromboxane A2 synthase inhibitor (IC50 is about 10 nM). Terbogrel is an antiplatelet compound that inhibits platelet aggregation and is a potential compound for the prevention of blood clots.

TPα/β antagonist-1 is a selective, dual thromboxane A2 receptor (TP receptor) antagonist that simultaneously targets both the TPα and TPβ subtypes, with IC₅₀ values of 1.52 nM and 0.79 nM, respectively. TPα/β antagonist-1 inhibits platelet aggregation. TPα/β antagonist-1 can be used in research on cardiovascular diseases.

LCB-2853 is a potent thromboxane A2/prostaglandin H2 (TXA2/PGH2) receptor antagonist with antiplatelet aggregation, antivasospasm, and antithrombotic effects.

RS-601 is a potent dual leukotriene D4/thromboxane A2 inhibitor that inhibits antigen-induced airway hyperresponsiveness (AHR) and shows asthmatic effects in a guinea pig model of asthma.

AZ-1355 is a novel dibenzoxepine derivative with lipid-lowering properties.

Daltroban (SKF 96148) is a specific thromboxane A2 (TXA2) receptor antagonist. Daltroban shows protective effect in reperfusion injury. Daltroban increase intracellular calcium in vascular smooth muscle cells.

Sulotroban potassium is a small molecule thromboxane A2 receptor (TXA2R) antagonist that can be used to study myocardial infarction and thrombosis.

Ozagrel (Domenan) is a selective thromboxane A(2) (TXA(2)) synthetase inhibitor with IC50 of 11 nM for rabbit platelet, used for the improvement of postoperative cerebrovascular contraction and accompanying cerebral ischaemia.

Ozagrel hydrochloride (OKY-046 HCl) is a selective thromboxane A(2) synthetase inhibitor used for the improvement of postoperative cerebrovascular contraction and accompanying cerebral ischaemia.

p-Hydroxycinnamic acid (NSC-59260) can inhibit platelet activity, with IC50s of 371 μM, 126 μM for thromboxane B2 production and lipopolysaccharide-induced prostaglandin E2 generation, respectively.

Seratrodast (ABT-001) (INN), a thromboxane A2 (TXA2) receptor (TP receptor) antagonist, is mainly used in the therapy of asthma. It was the first TP receptor antagonist developed as an anti-asthmatic drug and attained marketing qualification in Japan in 1997.

KP496 is a selective, dual antagonist for the Thromboxane A2 receptor (TP) and the Leukotriene D4 receptor (cysLT1).

NTP42 is an antagonist of thromboxane A2 (TXA2) receptor(IC50 of 3.278 nM)

L 888607 Racemate is a selective antagonist of the prostaglandin D2 receptor subtype 1 (DP1) with Ki values of 132 nM and 17 nM for DP1 and the thromboxane A2 receptor (TP), respectively.

Lcb 2853 is an antagonist of the thromboxane A2 receptor.

L-657926 is a stereoselective antagonist of the thromboxane A2 (TxA2) receptor, composed of (-)-9-chlorobenzyl-6-fluoro-1,2,3,4-tetrahydrocarbazol-1-yl acetic acid and (+)-9-chlorobenzyl-6-fluoro-1,2,3,4-tetrahydrocarbazol-1-yl acetic acid. The IC50 values for the (-) and (+) configurations against TxA2 are 0.27 nM and 124 nM, respectively.

TP receptor antagonist-3 (compound 51280) is a potent antagonist of the thromboxane A2 prostaglandin (TP) receptor, exhibiting an IC50 of 15.7 nM for Human TP. This compound is applicable in research related to Alzheimer's disease, cardiovascular and respiratory disorders, as well as cancer studies.

Picotamide monohydrate is a dual inhibitor of thromboxane A2 (TxA2) synthase and receptor. It exhibits antiplatelet activity and aids in reducing microalbuminuria and inhibiting carotid plaque growth in diabetes. This compound is applicable in research related to acute or chronic cardiovascular diseases.

Samixogrel functions as both an inhibitor of the thromboxane A2 receptor (thromboxane A2 receptor) and a suppressor of thromboxane synthesis (thromboxane synthesis).

BM 567 (compound 1) is a thromboxane A2 receptor (TXR) antagonist and thromboxane A2 synthase (TXS) inhibitor with anti-thrombotic effects, exhibiting IC₅₀ values of 1.1 and 12 nM respectively.

L-670,596 is a thromboxane A2/prostaglandin endoperoxide receptor antagonist.

Ici D1542 is a drug that exhibits both potent, selective TXS inhibition and TXA2 receptor antagonism. Ici D1542 is an effective thromboxane A2 synthase inhibitor and receptor antagonist in vitro.

L 657925 is an antagonist of the thromboxane A2 receptor.

11-deoxy-PGF2a is a thromboxane A2 receptor agonist that partially alleviates crowding in Lpar3(−/−) female embryos and induces smooth muscle contraction in the aorta, vena cava, and trachea.